ESR1 Gene Mutation
0
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
SciClone PharmaceuticalsChina - Shanghai
2 programsELacestrantN/A1 trial
Endocrine therapyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
SciClone PharmaceuticalsEndocrine therapy
SciClone PharmaceuticalsELacestrant
Clinical Trials (2)
Total enrollment: 800 patients across 2 trials
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
Start: Aug 2024Est. completion: Dec 2027450 patients
N/ARecruiting
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
Start: Jul 2024Est. completion: Aug 2026350 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 800 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.